A $100 million ad blitz has whipped up patient demand for Harvoni, the $1,100-a-pill hepatitis C treatment, even as the drug’s price has drawn a barrage of lawsuits, state investigations, and sharp ...
Jan 28 (Reuters) - UnitedHealth Group Inc on Wednesday backed Gilead Sciences Inc's hepatitis C treatment Harvoni on its 2015 commercial drug coverage list over a new competitor, Viekira Pak from ...
UnitedHealth Group Inc, the largest U.S. health insurer, has mentioned Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list. UnitedHealth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results